Press Releases :: CohBar, Inc. (CWBR)

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

The companies hosted a joint webcast on May 23, 2023, to discuss the transaction.

Morphogenesis Website

Access Webcast Replay

May 30, 2023 8:05am EDT

Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 23, 2023 7:30am EDT

CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

Nov 08, 2022 4:03pm EST

CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Oct 26, 2022 9:00am EDT

CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022

Sep 22, 2022 9:00am EDT

CohBar Announces Reverse Stock Split

Sep 06, 2022 9:00am EDT

CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference

Aug 15, 2022 4:02pm EDT

CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

Aug 01, 2022 9:00am EDT

CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022

Jul 12, 2022 9:00am EDT

CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

Jun 07, 2022 9:00am EDT

CohBar to Participate at Upcoming Conferences in June 2022